Friday February 12, 2021 0 comments
LONGMONT -- KromaTiD announced Colorado biomedical entrepreneur James Chomas has joined the company's board of directors.
Chomas has a track record of developing innovative healthcare solutions and driving adoption by customers and strategic partners. KromaTiD's sales and operations are rapidly accelerating and Chomas’ deep experience in healthcare product definition, commercialization, and organizational growth bring vital expertise to KromaTiD's board, the company said.
KromaTiD said its directional Genomic Hybridization or dGH provides the genomic structural context necessary to understand the potential risks of therapeutic gene editing -- critical measurements that can only be made with a single cell, genome-wide analysis such as dGH.
"We are excited to have Jim join our board as we move to accelerate commercialization of our IND-enabling genomic structural services to supplying gene therapy innovators world-wide," said Christopher Tompkins, KromaTiD's CEO and CTO.
"KromaTiD has developed an important and innovative advancement in understanding the integrity of the genome, which has broad applications in supporting CRISPR therapy development, uncovering genetic causes of undiagnosed diseases, and cancer diagnostics,” said Chomas.
“I'm honored to join the board and to partner with the KromaTiD team to drive commercial success in this exciting period of gene editing advancement."